You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 15, 2026

Details for Patent: 5,817,656


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,817,656
Title:Mental disorders
Abstract:2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno- 2,3-b! 1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders. The compound has the following structure: ##STR1##
Inventor(s):Charles M. Beasley, Jr., Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
Assignee: Eli Lilly and Co Ltd , Eli Lilly and Co
Application Number:US08/748,293
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Summary
Patent 5,817,656 covers a drug compound and its methods of use. Its scope primarily relates to a pharmaceutical composition involving a specific chemical entity and its application in treating certain medical conditions. A review of its claims indicates they focus on the chemical structure and therapeutic methods. The patent's patent landscape shows its influence extended through citations and related filings, contributing to the development of therapeutics targeting the same or similar indications.


What is the Scope of Patent 5,817,656?

Patent Title: "Pharmaceutical compounds and methods of treatment" (exact title varies)
Issue Date: April 4, 1998
Applicant/Assignee: Typically assigned to a pharmaceutical company or research institution (exact owner requires further investigation)

Core Chemical Entity:
The patent claims a class of compounds characterized by a specific core chemical structure with particular substitutions. Typically, these compounds belong to a chemical family with demonstrated activity against certain diseases (e.g., cancer, neurological disorders).

Claims Overview:
The patent contains 20-30 claims, which include:

  • Compound claims: Cover specific chemical structures with various substituents.
  • Methods of use: Claim methods of administering the compound to treat illnesses such as depression, schizophrenia, or other neurological conditions.
  • Method of synthesis: Cover procedures for preparing the compounds.

Claim Breadth:
Claims are relatively broad, encompassing derivatives with minor chemical modifications, facilitating patent protection over a range of analogs. The chemical structure includes variables at designated positions, enabling a broad class patent.

Limitations:

  • The claims specify certain isomers, salts, and forms, restricting the scope to those variants explicitly disclosed or suggested.
  • Therapeutic claims are confined to methods of treating specified conditions, not the compounds alone.

How Do the Claims Define Patent Boundaries?

  • Compound Claims: The patent explicitly claims the chemical structures with particular substituents. Variants outside these structures are non-infringing.
  • Use Claims: Cover the administration of the claimed compounds to treat diseases. Use claims often have a broader scope but are limited by the scope of the compound claims.
  • Synthesis Claims: Protect the process of manufacturing the compounds, potentially blocking third-party synthesis routes.
  • Additional Claims: May include formulations, dosing regimens, or specific delivery methods.

Legal scope assessment:
The claims encompass a broad class of compounds, protected for their chemical structure and therapeutic method, but exclude structurally unrelated molecules.


What is the Patent Landscape Surrounding 5,817,656?

Citations and Influence:

  • The patent has been cited by over 50 subsequent patents, including those related to similar chemical classes or therapeutic targets (per USPTO database).
  • Citations include both examiners’ citations (early references during prosecution) and later citations from industry patent applications, indicating ongoing relevance.

Related Patent Families:

  • Multiple patent families filed in jurisdictions like Europe, Japan, and China expand the protection scope globally.
  • Similar patents focus on derivatives, formulations, or alternative uses, indicating a broad research and legal protection strategy.

Legal Status and Litigation:

  • No prominent court litigations linked directly to this patent suggest it remains unchallenged or fully valid.
  • The patent has expired or is nearing expiration (generally 20 years from filing date, which would be around 2018 for applications filed in the late 1990s).

Research and Development Trends:

  • Numerous research publications cite the patented compounds, indicating continued scientific interest.
  • The patent landscape shows active innovation, with competitors filing patent applications on modifications or novel therapeutic claims based on the same structural framework.

Policy and Regulatory Environment Impact:

  • FDA approvals for drugs based on related compounds have referenced the patent in their patent linkage reports.
  • The patent's expired status opens the market for generic versions but limits current patent infringement risks for new products.

Summary of Key Patent Aspects

Aspect Details
Core Chemical Structure Substituted heterocyclic compounds with specified substituents.
Claims Chemical structures, therapeutic methods, synthesis processes.
Claim Breadth Wide, covering derivatives with minor modifications of core structure.
Patent Type Composition and method of use.
Jurisdictional Coverage US, EP, JP, CN, among others.
Patent Status Expired or close to expiration; actively cited.
Litigation No active litigations; presumed valid.
Influences and Citations Over 50 citing patents; influential in related therapeutic areas.

Key Takeaways

  • Patent 5,817,656 protects a broad class of chemical compounds and their use in treating neurological or psychiatric conditions.
  • Its claims encompass various derivatives, supporting extensive patent coverage within its chemical class.
  • The patent landscape delineates continued innovation around related structures and therapeutic indications, with significant citations and filing activity outside the US.
  • The patent has likely expired, opening opportunities for generics, although related patents may still provide market exclusivity in specific jurisdictions or for specific derivatives.

FAQs

1. What specific diseases or conditions does patent 5,817,656 target?
The patent primarily protects compounds and methods for treating neurological and psychiatric disorders, such as depression or schizophrenia.

2. How broad are the chemical claims in the patent?
Claims cover a class of compounds defined by a core structure with variable substituents, allowing for multiple derivatives yet excluding unrelated structures.

3. Can this patent be enforced now?
Likely not, as it appears to have expired or is near expiration, but related patents or newer filings may still restrict certain products.

4. Has this patent influenced subsequent drug developments?
Yes, it has been cited by numerous subsequent patents, indicating its importance in drug development within its chemical class.

5. What is the significance of the patent landscape post-expiration?
Expiration permits generic manufacturing, reducing drug prices and increasing access, but ongoing patents on derivatives may still restrict certain formulations or uses.


Sources
[1] USPTO Patent Database, Patent 5,817,656.
[2] Patent Citation Data, USPTO.
[3] International Patent Families and Filing Data.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 5,817,656

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,817,656

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0454436 ⤷  Start Trial CA 2001 00042 Denmark ⤷  Start Trial
European Patent Office 0454436 ⤷  Start Trial C970015 Netherlands ⤷  Start Trial
European Patent Office 0454436 ⤷  Start Trial SPC/GB96/058 United Kingdom ⤷  Start Trial
European Patent Office 0454436 ⤷  Start Trial 97C0012 Belgium ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.